[
    [
        {
            "time": "",
            "original_text": "【川财研究所*业绩点评】泰格医药（300347）：咨询业务毛利率大幅提升，期间费用率持续改善",
            "features": {
                "keywords": [
                    "泰格医药",
                    "咨询业务",
                    "毛利率",
                    "大幅提升",
                    "期间费用率",
                    "持续改善"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【川财研究所*业绩点评】泰格医药（300347）：咨询业务毛利率大幅提升，期间费用率持续改善",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]